Volenrelaxin for Chronic Kidney Disease
Trial Summary
Do I need to stop my current medications to join the trial?
You can continue your current medications if they are stable. You must stay on your ACE inhibitor or ARB and any other CKD or diabetes medications you are already taking.
What data supports the idea that Volenrelaxin for Chronic Kidney Disease is an effective drug?
The available research does not provide specific data on the effectiveness of Volenrelaxin for Chronic Kidney Disease. Instead, it highlights other treatments like renin-angiotensin system inhibitors, sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists as effective options. These treatments have shown significant benefits in managing kidney disease, such as reducing the risk of kidney damage and slowing disease progression. Without specific data on Volenrelaxin, it's unclear how it compares to these established treatments.12345
What safety data exists for Volenrelaxin (LY3540378) in treating chronic kidney disease?
The provided research does not contain specific safety data for Volenrelaxin (LY3540378) in the treatment of chronic kidney disease. The articles focus on other treatments such as SGLT2 inhibitors, mineralocorticoid receptor antagonists like finerenone, and their safety profiles. Further research or clinical trial data specific to Volenrelaxin would be needed to answer this question.13678
Is the drug Volenrelaxin a promising treatment for Chronic Kidney Disease?
What is the purpose of this trial?
The main purpose of this study is to investigate the efficacy and safety of Volenrelaxin in adults with Chronic Kidney Disease. The study will last about 24 weeks.
Research Team
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Eligibility Criteria
This trial is for adults with Chronic Kidney Disease. Specific eligibility details are not provided, but typically participants should meet certain health criteria and may be excluded based on factors that could impact the study's results or their own safety.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Volenrelaxin or placebo subcutaneously for the duration of the study
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Volenrelaxin
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University